Chimerix Inc
F:CXF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Chimerix Inc
F:CXF
|
US |
|
P
|
Prosus NV
OTC:PROSY
|
NL |
|
S
|
Sinopharm Group Co Ltd
OTC:SHTDF
|
CN |
|
S
|
Severn Trent PLC
DUS:SVT1
|
UK |
|
MSC Industrial Direct Co Inc
NYSE:MSM
|
US |
|
Vonovia SE
F:VNAA
|
DE |
|
Nanophase Technologies Corp
NASDAQ:SLSN
|
US |
|
P
|
Ping An Insurance Group Co of China Ltd
XMUN:PZX
|
CN |
|
Bukalapak.com Tbk PT
IDX:BUKA
|
ID |
|
S
|
Sif Holding NV
SWB:276
|
NL |
|
De' Longhi SpA
F:DLN
|
IT |
|
H
|
HEICO Corp
LSE:0J46
|
US |
|
M
|
Mercedes Benz Group AG
XBER:MBG
|
DE |
|
V
|
Vector Group Ltd
F:VGR
|
US |
|
T
|
Thermodynetics Inc
OTC:TDYT
|
US |
|
Asia Vital Components Co Ltd
OTC:AVMPF
|
TW |
|
Swiss Prime Site AG
SIX:SPSN
|
CH |
Chimerix Inc
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 87 full-time employees. The company went IPO on 2013-04-11. The firm is focused on discovering, developing and commercializing medicines that address unmet medical needs. The firm offers TEMBEXA (brincidofovir) is an antiviral for the treatment of smallpox in all age groups, including infants, and for patients who have difficulty swallowing. The firm's product Imipridones is a cancer therapies, which provides ONC201 for brain and other cancers, ONC206 for central nervous system cancer and ONC212 for pancreatic cancer and leukemia. The Company’s DSTAT is a glycosaminoglycan derivative of heparin, which is a treatment for hematologic malignancies, including newly diagnosed acute myeloid leukemia (AML) in combination with standard chemotherapy.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
